论文部分内容阅读
目的:观察肾炎康联合依那普利治疗糖尿病肾病的临床疗效。方法:选取2014年1月至2015年1月期间我院收治的糖尿病肾病患者100例,将患者随机分为观察组与对照组,每组各50例。两组患者均行常规治疗,对照组患者在此基础上联合依那普利进行治疗,观察组患者在对照组基础上再加以肾炎康联合治疗,对两组患者的治疗效果进行观察比较。结果:观察组患者治疗效果优于对照组,两组患者在24h蛋白尿、测肾小球滤过率(GER)、滤过分数(EF)和肾有效血流量(ERPF)指标上比较差异具有统计学意义(P<0.05)。结论:肾炎康联合依那普利治疗糖尿病肾病临床效果显著,可有效改善患者肾功能,优于单项依那普利治疗。
Objective: To observe the clinical efficacy of nesiritide and enalapril in the treatment of diabetic nephropathy. Methods: One hundred patients with diabetic nephropathy admitted in our hospital from January 2014 to January 2015 were randomly divided into observation group and control group, with 50 cases in each group. The two groups of patients underwent routine treatment. The patients in the control group were treated with enalapril on the basis of this. The patients in the observation group were treated with Shenyankang in combination with the control group. The therapeutic effects of the two groups were observed and compared. Results: The therapeutic effect of the observation group was better than that of the control group. There was significant difference in 24h proteinuria, GER, FEF and ERPF between the two groups Statistical significance (P <0.05). Conclusion: Shenyin Kang combined enalapril treatment of diabetic nephropathy clinically significant effect, which can effectively improve the renal function in patients, superior to enalapril enalapril treatment.